Icon

Xopenex HFA - (EQ 0.045MG BASE/INH; Aerosol, Metered: Inhalation)

Levalbuterol Tartrate Sunovion Pharma
EQ 0.045MG BASE/INH; Aerosol, Metered: Inhalation
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
None None
Indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.
Yes
****** ** ****** ** ** *** *** **** **** ** **** ****** '***(*** *, ****) *** ************ ********* ** ********. ******* ********** *** ******* **** ****** ********* ** *** ***** ** ***** ****** ******** ** ** ** *** ****. ***** ***** * **** ******* ******** ******** **** ********'* ******* ******* *** ********* *****'* ****** ** ’*** ******, ****** “******* *** ********* ******* ** **********" **** *** ****** ** ***** ** *** ****. ***** ***** *** ******* *** ******* ** *** **********. ******* ***** *** ********** *** ********* ******* ***** *** ******** ***** *** ***** ** ********* *** *** *****. ** ** ********* ** **** **** **** * ********** ******* ** ***** **** ***** *** ****** *** ********** ***** ** ****** **** ***** **** *** **** ****** ** ******* **** *** *****.
Xopenex HFA Patent 1 Patent 2
****** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** **, **** ******* **** ******** ** *** *, **** ** **
  1. **** **, **** : ****** ******** ******** ***** *** **** ** *********** ****** '***- *** *, ****.
  2. **** **, **** : ******** **** ****** ** ******** ***** ** ********
  3. *** *, **** : ****** ** ’*** ******, ****** “******* *** ********* ******* ** **********" *** ****** ** *****. *****'* ****** **** *** *** ****** ** *** ********* *** ** ****** ** ** ** ********* ** ****.
  4. *** **, **** : ***** ***** * **** ******* ******** ******* **** ******** ********* *****'* ****** **'***.
  5. *** **, **** : ********** *** ********* **** ****** ********* ** *** ***** ** ***** ****** ******* ******* ** *** *** ******* *** ** *** *, ****.
  6. *** **, **** : ***** **** * ********** ******* ****** **** ** ****** ** *** *** ***** ************ ** ****** ** *****.
  7. *** **, **** : ********** *** ********* ******* ***** *** ******** ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.